trending Market Intelligence /marketintelligence/en/news-insights/trending/WKHjtfsGv9Rfi3h05CaNIg2 content esgSubNav
In This List

Akcea seeks EMA approval for rare disorder drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Akcea seeks EMA approval for rare disorder drug

Akcea Therapeutics Inc. filed an application with the European Medicines Agency, seeking approval for a treatment of a rare genetic disorder.

Volanesorsen is meant for patients with the familial chylomicronemia syndrome which results in abdominal pain and potentially fatal bouts of pancreatitis, the inflammation of the pancreas.

Akcea, a unit of Ionis Pharmaceuticals Inc., will also file applications for its drug in Canada and the U.S. in September.